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INTRODUCTION
Dengue fever (DF) is a global health problem.(1) While the 
main manifestation in severe dengue disease (SDD) is primarily 
haemorrhage, dengue hepatitis is an increasingly well-known 
complication of SDD.(2-4) In severe hepatitis, fulminant hepatic 
failure (FHF) has been reported.(5-6) The new World Health 
Organization (WHO) guidelines for DF recommend the 
administration of paracetamol (PCM) for high fever if the patient 
is uncomfortable.(7) However, these guidelines do not specify 
whether PCM should be given in the presence of hepatitis.(7)
 We report the case of an eight-month-old infant with SDD 
who was given therapeutic doses of PCM for fever. The illness 
was complicated by FHF. This case highlights the risk of severe 
liver injury in children with acute dengue hepatitis who are 
given repeated therapeutic doses of PCM.
CASE REPORT
An eight-month-old female infant was referred for further 
management of SDD, encephalopathy, coagulopathy and 
hepatitis. Her fever had started 13 days ago. She was admitted 
to a local hospital on Day 4 of the illness with a temperature of 
39.0°C and a generalised maculopapular rash. There was no history 
of use of herbs or other traditional medicine. There was also no 
other signs that would suggest the presence of other concomitant 
infections. On admission, her haemoglobin level was 62 g/L, white 
blood cells was 7.4 × 109/L and platelet count was 33 × 109/L. 
Dengue NS1 antigen and dengue serology immunoglobulin M 
were both positive. The patient developed an episode of 
generalised seizures soon after admission. Intravenous fluids 
were started and her condition improved. Despite the decrease 
in haematocrit level (48% on Day 5 of illness, 33% on Day 6, 
31% on Day 7), the patient received intravenous fluids at 
4 mL/kg/hr (0.45% saline, 5% dextrose solutions).
 On Day 11 of illness, the patient had haematemesis. She 
was jaundiced and had fluid overload. Her liver enzymes were 
markedly raised, with aspartate transferase (AST) at 1,539 IU/L 
and alanine transferase (ALT) at 5,497 IU/L. There was no liver 
function test done before this. The international normalised 
ratio (INR) was 2.89 and prothrombin time (PT) was 26.4 s. 
She was referred to the paediatric intensive care unit of University 
Malaya Medical Centre for further management. A review of the 
patient’s treatment at the referring hospital showed that she had 
been given regular PCM at a dose of 105 mg (15 mg/kg/dose), 
four times a day for a total of seven days. On examination, the 
patient appeared ill, oedematous, jaundiced, pale and very drowsy. 
There was a generalised petechial rash, hepatosplenomegaly, 
gross ascites and bilateral basal crepitations over both lungs. 
Haematemesis and malaena were present. There was also 
generalised hypertonia and hyperreflexia of all four limbs (hepatic 
encephalopathy grade III).(8) She was intubated and ventilated 
immediately. The diagnosis was post-dengue shock syndrome 
with FHF, possibly contributed by PCM overdose.
 The patient’s initial blood investigations showed total 
bilirubin 178 µmol/L, conjugated bilirubin 111 µmol/L, AST 
2,684 IU/L, ALT 806 IU/L, alkaline phosphatase 806 IU/L, 
creatinine 26 µmol/L and serum ammonia 170.5 µmol/L, 
with coagulopathy (INR > 8, PT > 100 s, activated partial 
thromboplastin time 76.8 s, D-dimer test positive). Serum PCM 
level at 20 hours after the last dose was 0.1 mmol/L above the 
PCM treatment nomogram.(9) The illness was complicated by 
hypoglycaemia-induced seizures and upper gastrointestinal 
bleeding. A computed tomographic examination of the brain 
showed no intracranial bleeding or cerebral oedema. The 
patient was given multiple transfusions of blood products and 
intravenous vitamin K. Intravenous infusion of N-acetylcysteine at 
a dose of 10 mg/kg/hr was commenced. She was encephalopathic 
Regular paracetamol in severe dengue: a lethal 
combination? 
Chin Seng Gan1, MBBS, MPaeds, Sze Yee Chong1, MD, MPaeds, Lucy Chai See Lum1, MBBS, MRCP, 
Way Seah Lee1, MD, FRCPH
1Department of Paediatrics, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Correspondence: Dr Way Seah Lee, Professor, Department of Paediatrics, University Malaya Medical Centre, Kuala Lumpur 59100, Malaysia. leews@um.edu.my
ABSTRACT An eight-month-old female infant with severe dengue disease, who was repeatedly given therapeutic  
paracetamol for severe dengue, developed fulminant liver failure with encephalopathy, gastrointestinal haemorrhage 
and severe coagulopathy. She responded to supportive measures and N-acetylcysteine infusion. This case highlights 
the potential danger of administering repeated therapeutic doses of paracetamol in childhood severe dengue disease  
with hepatitis.
Keywords: hepatitis, paracetamol, severe dengue 
Singapore Med J 2013; 54(2): e35–e37
Singapore Med J 2013; 54(2) : e36
C ase R epor t
for seven days. INR (> 8.0) and PT (> 100 s) were persistently 
deranged despite repeated transfusion of blood products. The 
subsequent course was also complicated by hospital-acquired 
infections. As emergency liver transplantation for FHF in young 
infants is not available in Malaysia, supportive measures were 
continued. On Day 15 of admission, the patient’s coagulation 
profiles gradually improved. She was extubated on Day 18. Upon 
discharge from the hospital on Day 25, she still had residual left 
hemiparesis. At follow-up review two months after the initial 
illness, no residual neurological deficit was noted.
 
DISCUSSION
FHF due to PCM overdose may be due to either a single large 
overdose or cumulative, multiple overdoses.(10,11) The latter has 
been increasingly recognised as an important cause of FHF due 
to PCM overdose.(11) In a recent Australian and New Zealand 
guidelines for the management of PCM poisoning, a single dose 
of 200 mg/kg or more of PCM ingestion over a period of less than 
eight hours in children younger than six years old is considered 
likely to be associated with hepatic injury.(9) For those with 
repeated supratherapeutic ingestion, the doses are considerably 
lower, depending on the duration of ingestion.(9) However, the 
guidelines did not specify the dose that may possibly be associated 
with liver injury in children with pre-existing liver conditions.(9) 
Mild to moderate hepatitis is common in dengue, with its 
occurrence reported in 71% of children with dengue. Severe 
hepatitis (serum ALT > 300 IU/L) was noted in 15%.(4) The 
mortality rate of children with severe hepatitis in dengue was 
67%.(4) Hence, hepatic involvement should be suspected in all 
patients, not only in those with DF, but possibly also in those 
with other viral or fulminant bacterial infections. Liver functions 
should be determined early, and in cases of prolonged fever, at 
regular intervals.
 Our patient had clinical evidence of severe dengue with 
supportive dengue serology. During the course of her illness, 
she was given repeated therapeutic doses of PCM for one week. 
Her serum PCM level was within the toxic range. Arguably, it is 
difficult to ascertain whether repeated administration of PCM 
in this patient ultimately resulted in FHF, as both severe dengue 
and repeated PCM administration can lead to hepatic injury. 
There have not been many case reports on the effect of repeated 
PCM administration in therapeutic doses and its effect on liver 
function in patients with SDD, although some authors have 
advised checking for liver enzymes profile before administration 
of PCM in patients suspected of SDD.(12) There have been 
evidences, however, both in vitro and in vivo, that the metabolism 
of PCM is reduced in patients with hepatitis.(13,14) Although 
at present, there is no study on the metabolism of PCM in cases 
of dengue complicated by concomitant hepatitis, it is likely that 
the result may be significant. The new WHO guidelines on DF 
allows PCM to be prescribed to relieve discomfort from fever.(7) 
However, there is no clear guideline on the regular use of PCM 
in DF complicated by dengue hepatitis. Caution should thus be 
exercised when giving repeated therapeutic doses of PCM in 
children with hepatitis, even in the absence of hepatic function 
impairment.
 Since hepatitis is common in childhood dengue haemorrhagic 
fever, we suggest that screening for hepatic function derangement 
be done in all cases of SDD. In children with SDD and deranged 
liver enzyme levels, considerable care should be exercised 
when PCM is prescribed for the relief of fever. We suggest that 
therapeutic dosing should not always be at the maximum dose 
even though the recommended therapeutic dose of PCM is 
10–15 mg/kg (of body weight) four times daily. Additionally, in 
the presence of hepatic involvement, clinicians should consider 
reducing the doses of drugs that are metabolised by the liver, 
including PCM. Dosing should be guided by the monitoring 
of the serum levels of the drug prescribed. At present, WHO 
guidelines do not encourage the use of other nonsteroidal anti-
inflammatory drugs, such as ibuprofen or antipyretics, in DF. 
In this aspect, WHO’s guidelines on dengue should also be 
updated to clarify the indications, dosing levels, duration and a 
safe antipyretic alternative for children with DF.(7)
 Although the prognosis of FHF secondary to PCM is generally 
quite favourable with a spontaneous recovery rate of 94%, 
patients with grade III encephalopathy have a recovery rate of 
only 33%.(10) In conclusion, in our report of a young infant with 
dengue haemorrhagic fever complicated by FHF, we suggest 
caution in the administration of repeated therapeutic doses of 
PCM in children with dengue or other medical conditions where 
the metabolism of PCM could be impaired.
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